The effect of rheumatoid arthritis-associated autoantibodies on the incidence of cardiovascular events in a large inception cohort of early inflammatory arthritis

Rheumatology (United Kingdom)

Volumn 56, Issue 5, 2017, Pages 768-776

  Barra, Lillian J ^a   Pope, Janet E ^a   Hitchon, Carol ^b,i   Boire, Gilles ^c,i   Schieir, Orit ^d   Lin, Daming ^e   Thorne, Carter J ^f   Tin, Diane ^f   Keystone, Edward C ^e,i   Haraoui, Boulos ^g   Jamal, Shahin ^h   Bykerk, Vivian P ^e,i   Ahluwalia, V ⁱ   Akhavan, P ⁱ   Barra, L ⁱ   Barber, C ⁱ   Barnabe, C ⁱ   Bartlett, S ⁱ   Baron, M ⁱ   Bessette, L ⁱ   Colmegna, I ⁱ   Fallavollita, S ⁱ   Haaland, D ⁱ   Haraoui, B ⁱ   Hazlewood, G ⁱ   Jamal, S ⁱ   Kuriya, B ⁱ   Larche, M ⁱ   Lyddell, C ⁱ   Nair, B ⁱ   Penney, C ⁱ   Pope, J ⁱ   Rubin, L ⁱ   Tremblay, J L ⁱ   Thorne, C ⁱ   Villeneuve, S ⁱ   Zummer, M ⁱ   more..

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITÉ DE SHERBROOKE   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e MOUNT SINAI HOSPITAL   (Canada)

^f SOUTHLAKE REGIONAL HEALTH CENTRE   (Canada)

^g UNIVERSITÉ DE MONTRÉAL   (Canada)

^h VANCOUVER COASTAL HEALTH   (Canada)

ⁱ HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

ACPA; Cardiovascular disease; Complications; RF; Rheumatoid arthritis; Seropositive

Indexed keywords

AUTOANTIBODY; CORTICOSTEROID; METHOTREXATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; RHEUMATOID FACTOR;

ACUTE CORONARY SYNDROME; ADULT; AGE; ARTICLE; ATTRIBUTABLE RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE DURATION; DRUG USE; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBESITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SELF REPORT; ANALYSIS OF VARIANCE; ARTHRITIS, RHEUMATOID; CANADA; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COMPLICATION; IMMUNOLOGY; INCIDENCE; KAPLAN MEIER METHOD; METABOLISM; MULTICENTER STUDY; RISK FACTOR;

ANALYSIS OF VARIANCE; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CANADA; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; HYPERTENSION; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PROSPECTIVE STUDIES; RHEUMATOID FACTOR; RISK FACTORS;

EID: 85019687833     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kew474     Document Type: Article

References (50)

1. Aviña-Zubieta JA, Choi HK, Sadatsafavi M et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008;59:1690-7
2. Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2012;71:1524-9
3. Maradit-Kremers H, Crowson CS, Nicola PJ et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005;52:402-11
4. Holmqvist ME, Wedrén S, Jacobsson LT et al. No increased occurrence of ischemic heart disease prior to the onset of rheumatoid arthritis: results from two Swedish population-based rheumatoid arthritis cohorts. Arthritis Rheum 2009;60:2861-9
5. Kerola AM, Kauppi MJ, Kerola T, Nieminen TV. How early in the course of rheumatoid arthritis does the excess cardiovascular risk appear? Ann Rheum Dis 2012;71:1606-15
6. Hannawi S, Marwick TH, Thomas R. Inflammation predicts accelerated brachial arterial wall changes in patients with recent-onset rheumatoid arthritis. Arthritis Res Ther 2009;11:R51
7. Chung CP, Oeser A, Raggi P et al. Increased coronaryartery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum 2005;52:3045-53
8. Baghdadi LR, Woodman RJ, Shanahan EM, Mangoni AA. The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. PLoS One 2015;10:e0117952
9. Mantel Ä, Holmqvist M, Nyberg F et al. Risk factors for the rapid increase in risk of acute coronary events in patients with new-onset rheumatoid arthritis: a nested case-control study. Arthritis Rheumatol 2015;67:2845-54
10. Solomon DH, Reed GW, Kremer JM et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol 2015;67:1449-55
11. Ajeganova S, Andersson ML, Frostegard J, Hafström I. Disease factors in early rheumatoid arthritis are associated with differential risks for cardiovascular events and mortality depending on age at onset: a 10-year observational cohort study. J Rheumatol 2013;40:1958-66
12. Innala L, Möller B, Ljung L et al. Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study. Arthritis Res Ther 2011;13:R131
13. Taylor P, Gartemann J, Hsieh J, Creeden J. A systematic review of serum biomarkers anti-cyclic citrullinated peptide and rheumatoid factor as tests for rheumatoid arthritis. Autoimmune Dis 2011;2011:815038
14. Hill JA, Bell DA, Brintnell W et al. Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice. J Exp Med 2008;205:967-79
15. Kinloch AJ, Alzabin S, Brintnell W et al. Immunization with Porphyromonas gingivalis enolase induces autoimmunity to mammalian a-enolase and arthritis in DR4-IE-transgenic mice. Arthritis Rheum 2011;63:3818-23
16. Petkova SB, Konstantinov KN, Sproule TJ et al. Human antibodies induce arthritis in mice deficient in the lowaffinity inhibitory IgG receptor FcgRIIB. J Exp Med 2006;203:275-80
17. Sokolove J, Brennan MJ, Sharpe O et al. Brief report: citrullination within the atherosclerotic plaque: a potential target for the anti-citrullinated protein antibody response in rheumatoid arthritis. Arthritis Rheum 2013;65:1719-24
18. Lundström E, Källberg H, Alfredsson L, Klareskog L, Padyukov L. Gene-environment interaction between the DRB1 shared epitope and smoking in the risk of anticitrullinated protein antibody-positive rheumatoid arthritis: all alleles are important. Arthritis Rheum 2009;60:1597-603
19. Gonzalez A, Icen M, Kremers HM et al. Mortality trends in rheumatoid arthritis: the role of rheumatoid factor. J Rheumatol 2008;35:1009-14
20. Farragher TM, Goodson NJ, Naseem H et al. Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. Arthritis Rheum 2008;58:359-69
21. López-Longo FJ, Oliver-Miñarro D, de la Torre I et al. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum 2009;61:419-24
22. Goodson N, Marks J, Lunt M, Symmons D. Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Ann Rheum Dis 2005;64:1595-601
23. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005;52:722-32
24. Mackey RH, Kuller LH, Deane KD et al. Rheumatoid arthritis, anti-cyclic citrullinated peptide positivity, and cardiovascular disease risk in the women's health initiative. Arthritis Rheumatol 2015;67:2311-22
25. Young A, Koduri G, Batley M et al. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology 2007;46:350-7
26. Ajeganova S, Humphreys JH, Verheul MK et al. Anticitrullinated protein antibodies and rheumatoid factor are associated with increased mortality but with different causes of death in patients with rheumatoid arthritis: a longitudinal study in three European cohorts. Ann Rheum Dis 2016;75:1924-32
27. Cheng CK, McDonald-Blumer H, Boire G et al. Care gap in patients with early inflammatory arthritis with a high fracture risk identified using FRAX;. J Rheumatol 2010;37:2221-5
28. Skeoch S, Bruce IN. Atherosclerosis in rheumatoid arthritis: is it all about inflammation? Nat Rev Rheumatol 2015;11:390-400
29. Gonzalez A, Maradit Kremers H, Crowson CS et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann Rheum Dis 2008;67:64-9
30. Escalante A, Haas RW, del Rincón I. Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med 2005;165:1624-9
31. Myasoedova E, Crowson CS, Kremers HM et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 2011;70:482-7
32. Rantapää-Dahlqvist S, Wallberg-Jonsson S, Dahleń G. Lipoprotein (a), lipids, and lipoproteins in patients with rheumatoid arthritis. Ann Rheum Dis 1991;50:366-8
33. Boers M, Nurmohamed MT, Doelman CJ et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:842-5
34. Hahn BH, Grossman J, Chen W, McMahon M. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun 2007;28:69-75
35. Georgiadis AN, Papavasiliou EC, Lourida ES et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment-a prospective, controlled study. Arthritis Res Ther 2006;8:R82
36. Yang G, Bykerk VP, Boire G et al. Does socioeconomic status affect outcomes in early inflammatory arthritis? Data from a Canadian multisite suspected rheumatoid arthritis inception cohort. J Rheumatol 2015;42:46-54
37. Widdifield J, Bernatsky S, Paterson JM et al. Trends in excess mortality among patients with rheumatoid arthritis in Ontario, Canada. Arthritis Care Res 2015;67:1047-53
38. Humphreys JH, Warner A, Chipping J et al. Mortality trends in patients with early rheumatoid arthritis over 20 years: results from the Norfolk Arthritis Register. Arthritis Care Res 2014;66:1296-301
39. Meune C, TouzéE, Trinquart L, Allanore Y. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology 2009;48:1309-13
40. Wielgosz A, Arango M, Bancej C et al. Tracking heart disease and stroke in Canada. Ottawa, ON, Canada: Public Health Agency of Canada, 2009
41. Lacaille D, Sayre EC, Abrahamowicz M. Improvement in mortality in RA compared to the general population-closing the mortality gap [abstract]. Arthritis Rheumatol 2015;67(Suppl 10):abstract 1999
42. Myasoedova E, Crowson CS, Matteson EL et al. Decreased cardiovascular mortality in patients with incident rheumatoid arthritis (RA) in recent years: dawn of a new era in cardiovascular disease in RA? Arthritis Rheumatol 2015;67(Suppl 10):abstract 3237
43. Roubille C, Richer V, Starnino T et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2015;74:480-9
44. Barnabe C, Martin BJ, Ghali WA. Systematic review and meta-analysis: anti-tumor necrosis factor a therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res 2011;63:522-9
45. Provan SA, Berg IJ, Hammer HB et al. The impact of newer biological disease modifying anti-rheumatic drugs on cardiovascular risk factors: a 12-month longitudinal study in rheumatoid arthritis patients treated with rituximab, abatacept and tociliziumab. PLoS One 2015;10:e0130709
46. Roubille C, Richer V, Starnino T et al. Evidence-based recommendations for the management of comorbidities in rheumatoid arthritis, psoriasis, and psoriatic arthritis: expert opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative. J Rheumatol 2015;42:1767-80
47. Martín-Martínez MA, González-Juanatey C, Castañeda S et al. Recommendations for the management of cardiovascular risk in patients with rheumatoid arthritis: scientific evidence and expert opinion. Semin Arthritis Rheum 2014;44:1-8
48. Peters MJ, Symmons DP, McCarey D et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69:325-31
49. Kremers HM1, Crowson CS, Therneau TM, Roger VL, Gabriel SE. High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: a population-based cohort study. Arthritis Rheum 2008;58:2268-74
50. van Breukelen-van der Stoep DF, van Zeben D, Klop B, van de Geijn GM et al. Marked underdiagnosis and undertreatment of hypertension and hypercholesterolaemia in rheumatoid arthritis. Rheumatology 2016;55:1210-6